Summary
Changing attitudes towards the use of antiepileptic drugs have led to an emphasis on monotherapy with serum concentration measurement coupled with standard, weight-adjusted starting and maintenance regimens to guide initial therapy and subsequent dosage titration. Currently, the established anticonvulsants are carbamazepine, valproic acid (sodium valproate) and phenytoin. Phenobarbital is now less commonly prescribed due to its propensity to produce sedation and impair cognitive function.
The value of pharmacokinetic optimisation with valproic acid is limited by its wide therapeutic index, large fluctuations in the concentration-time profile and concentration-dependent protein binding. Thus, although serum concentrations are often measured, they are rarely subjected to pharmacokinetic interpretation. Carbamazepine has a flatter concentration-time profile than valproic acid. Its target range is more clearly defined and it undergoes autoinduction of metabolism and interacts with other drugs. Pharmacokinetic principles can, therefore, be more readily applied to carbamazepine, although, in general, a simple clinical approach to its use is usually satisfactory.
Phenytoin has required the greatest pharmacokinetic input due to its nonlinear pharmacokinetics and narrow target range. Many different graphical methods, equations and computer programs have been reported, some of which demand 2 steady-state, dose-concentration pairs; others function satisfactorily with only 1. Recent attempts have been made to interpret non-steady-state data. In addition, a number of workers have demonstrated the value of altering the population parameter estimates to account for ethnic differences. A pharmacokinetic approach can also be used to tailor the use of phenytoin in the treatment of status epilepticus.
Dosage alterations may be needed for specific patient groups. In particular, children generally require higher dosages on a weight-for-weight basis than adults, while equivalently lower dosages should be given to neonates. Most anticonvulsants are principally cleared by hepatic mechanisms, so dosage adjustment is not usually required in renal disease, although care must be taken in interpreting serum concentrations because of changes in protein binding. Close monitoring is required in the elderly and patients with hepatic impairment, while increased dosages may be needed in critically ill patients and during pregnancy. Pharmacokinetic principles can be used in the treatment of treat self-poisoning with anticonvulsants.
There are few data available on the pharmacokinetics of vigabatrin, lamotrigine, oxcarbazepine and gabapentin in patients. Due to its mode of action in binding irreversibly to its target enzyme, serum concentration monitoring of vigabatrin plays no role in optimising therapy. The value of applying pharmacokinetic principles with the other 3 drugs remains to be investigated. Of these, lamotrigine seems the most likely candidate for a pharmacokinetic approach.
Similar content being viewed by others
References
Armijo JA, Cavada E. Graphic estimation of phenytoin dose in adults and children. Therapeutic Drug Monitoring 13: 507–510, 1991
Bartosyk GD, Meyerson W, Reimann W, Satzinger G, Von Hodenborg A. Gabapentin. In Meldrum BS, Porter RJ (Eds) Current problems in epilepsy 4: new anticonvulsant drugs, pp. 147–168, John Libby, London, 1986
Battino D, Bossi L, Croci D, Franceschetti S, Gomeni C, et al. Carbamazepine plasma levels in children and adults: influence of age, dose and associated therapy. Therapeutic Drug Monitoring 2: 315–322, 1980
Beghi E, Di Mascio R, Tognoni G. Drug treatment of epilepsy: outlines, criticism and perspectives. Drugs 31: 249–265, 1986
Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes — autoinduction of carbamazepine epoxidation Journal of Clinical Pharmacology 26: 459–462, 1986
Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical Pharmacokinetics 22: 11–21, 1992
Binnie CD, Debets RMC, Engelsman M, Meijer JWA, Meinhardi H, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Research 1989 4: 222–229, 1989
Binnie CD, Van Emde-Boas W, Kasteleijn-Nolste-Trenite DGA, De Korta RA, Meijer JWA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27: 248–254, 1986
Blaser KU, Vozeh S, Landolt H, Kaufmann G, Romppainen J, et al. Intravenous phenytoin: a loading scheme for desired concentrations. Annals of Internal Medicine 110: 1029–1031, 1989
Boucher BA, Rodman JH, Fabian TC, Cupit GC, Ludden TM, et al. Disposition of phenytoin in critically ill trauma patients. Clinical Pharmacy 6: 881–887, 1987
Boucher BA, Rodman JH, Jaresko GS, Rasmussen SN, Watridge CB, et al. Phenytoin pharmacokinetics in critically ill trauma patients. Clinical Pharmacology and Therapeutics 44: 675–683, 1988
Bourgeois BFD. Valproate: clinical use. In Levy R et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 633–642, Raven Press, New York, 1989
Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet 336: 350–354, 1990a
Brodie MJ. Management of epilepsy during pregnancy and lactation. Lancet 336: 426–427, 1990b
Brodie MJ. Status epilepticus in adults. Lancet 336: 551–552, 1990c
Brodie MJ. Drug interactions and epilepsy. Epilepsia, in press, 1992a
Brodie MJ. Lamotrigine. Lancet, in press, 1992b
Brodie MJ, Feely J. Practical clinical pharmacology. Therapeutic drug monitoring and clinical trials British Medical Journal 296: 1110–1114, 1988
Brodie MJ, Forrest G, Rapeport WG. Carbamazepine 10,11-epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. British Journal of Clinical Pharmacology 16: 747–750, 1983
Brodie MJ, McPhail E, Macphee GJA, Larkin JG, Gray JMB. Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. European Journal of Clinical Pharmacology 31: 655–660, 1987
Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet 336: 425–426, 1990
Browne T. The pharmacokinetics of agents used to treat status epilepticus. Neurology 40 (Suppl. 2): 29–42, 1990
Bryson SM, Al-Lanqawi Y, Kelman AW, Whiting B. Comparison of a Bayesian forecasting technique with a new method for estimating phenytoin dose requirements. Therapeutic Drug Monitoring 10: 80–84, 1988
Chadwick DW. Diagnosis of epilepsy. Lancet 336: 291–295, 1990a
Chadwick D. Gabapentin in partial epilepsy. Lancet 335: 1114–1117, 1990a
Chaikin P, Adir J. Unusual absorption profile of phenytoin in a massive overdose case. Journal of Clinical Pharmacology 27: 70–73, 1987
Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants: state of the art. Clinical Pharmacokinetics 18: 318–328, 1990
Chrystyn H, Morgan DH. A comparison of graphical nomogram methods with a computerised Bayesian analysis method in the interpretation of serum phenytoin concentrations. Journal of Clinical and Hospital Pharmacy 11: 443–448, 1986
Crawford P, Ghadali E, Lane R, Bumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. Journal of Neurology, Neurosurgery and Psychiatry 50: 682–686, 1987
Crawford TO, Mitchell WG, Fishman LS, Snodgrass SR. Very-high-dose phenobarbital for refractory status epilepticus in children. Neurology 38: 1035–1040, 1988
Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. European Journal of Clinical Pharmacology 32: 141–148, 1987
Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research 3: 70–76, 1989
Duncan JS, Patsalos PN, Shorvon SD. Effects of discontinuation of phenytoin, carbamazepine and valproate on concomitant antiepileptic medication. Epilepsia 32: 101–115, 1991
Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Incidence, clinical features and management. Medical Toxicology and Adverse Drug Experience 4: 95–107, 1989
Eadie MJ. Plasma monitoring of anticonvulsants. Clinical Pharmacokinetics 1: 52–66, 1976
Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing plasma phenobarbitone levels in epileptic patients. British Journal of Clinical Pharmacology 4: 541–547, 1977
Editorial. Sodium valproate. Lancet 2: 1229–1231, 1988
Editorial. Vigabatrin. Lancet 1: 532–533, 1989a
Editorial. Oxcarbazepine. Lancet 2: 196–198, 1989b
Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clinical Pharmacokinetics 10: 80–90, 1985
Farrell K, Abbott FS, Orr JM, et al. Free and total valproate concentrations their relationship to seizure control, liver enzymes and plasma ammonia in children. Canadian Journal of Neurological Science 13: 252–255, 1986
Flint N, Lopez LM, Robinson JD, Williams C, Salem RB. Comparison of eight phenytoin dosing methods in institutionalised patients. Therapeutic Drug Monitoring 7: 74–80, 1985
Gabor AJ. Lorazepam versus phenobarbital: candidate for drug of choice for treatment of status epilepticus. Journal of Epilepsy 3: 3–6, 1990
Garcia MJ, Alonso AC, Maza A, Santos D, Matesanz C, et al. Comparison of methods of carbamazepine dosage individualisation in epileptic patients. Journal of Clinical Pharmacy and Therapeutics 13: 375–380, 1988
Gillham RA, Williams M, Weidmann K, Butler E, Larkin JG, et al. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. Journal of Neurology, Neurosurgery and Psychiatry 51: 929–933, 1988
Gillman ME, Toback JW, Gal P, Erikan NV. Individualising phenobarbital dosing in neonates. Clinical Pharmacy 2: 258–262, 1983
Gillman JT, Gal P, Duchowny MS, Weaver RL, Ransom JL. Rapid sequential phenobarbital treatment of neonatal seizures. Paediatrics 83: 674–678, 1989
Godley PJ, Ludden TM, Clemanti WA, Godley SE, Ramsay RR. Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations. Clinical Pharmacy 6: 634–639, 1987
Grant SM, Heel RC. Vigabatrin. Drugs 41: 889–926, 1991
Graves NM, Leppik IE, Termond E, Taylor JW. Phenytoin clearances in a compliant population: description and application. Therapeutic Drug Monitoring 8: 427–433, 1986
Haegele KD, Huebert ND, Erel M, Tell GP, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clinical Pharmacology and Therapeutics 44: 558–585, 1988
Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate — a 5-year follow-up study of 100 children with epilepsy. Acta Neurologica Scandinavica 65: 504–523, 1982
Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacology and Therapeutics 40: 439–474, 1989
Hudson SA, Farquhar DL, Thompson D, Smith RG. Phenytoin dosage individualisation — five methods compared in the elderly. Journal of Clinical Pharmacy and Therapeutics 15: 25–34, 1990
Jawad S, Richens A, Goodwin G, Yuen AWC. Controlled trial of lamotrigine for refractory partial seizures. Epilepsia 30: 356–363, 1989
Jawad S, Yuen AWC, Peck AW, Hamilton MJ, Oxley JR, et al. Lamotrigine: single-dose pharmacokinetics and initial one-week experience in refractory seizures. Epilepsy Research 1: 194–201, 1987
Johannessen SI. Antiepileptic drugs: pharmacokinetic and clinical aspects. Therapeutic Drug Monitoring 3: 17–37, 1981
Johnson FN, Brodie MJ. Pharmacokinetics of carbamazepine: implications for clinical use. Reviews in Contemporary Pharmacotherapy 1: 85–98, 1990
Kelman AW, Whiting B, Bryson SM. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. British Journal of Clinical Pharmacology 14: 247–256, 1982
Killilea T, Coleman R, Ludden T, Peck CC, Rose D. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Therapeutic Drug Monitoring 11: 455–462, 1989
Larkin JG, Herrick AL, McGuire GM, Percy-Robb I, Brodie MJ. Antiepileptic drug monitoring at the epilepsy clinic: a prospective evaluation. Epilepsia 32: 89–95, 1991
Larkin JG, McKee PJ, Brodie MJ. Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients. British Journal of Clinical Pharmacology 33: 1111–1114, 1992
Larkin JG, McKee PJ, Forrest G, Beastall GH, Park BK, et al. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. British Journal of Clinical Pharmacology 31: 65–71, 1991b
Larkin JG, McLellan A, Munday A, Sutherland M, Butler E, et al. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. British Journal of Clinical Pharmacology 27: 313–322, 1989
Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. Journal of Clinical Psychiatry 49 (Suppl. 4): 58–62, 1988
Loiseau P, Yuen AWC, Duche B, Menager T, Arne-Bes MC. A randomised double-blind, placebo-controlled, crossover addon trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Research 7: 136–145, 1990
Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, et al. Individualisation of phenytoin dosage regimens. Clinical Pharmacology and Therapeutics 21: 287–293, 1977
Ludden TM, Beal SL, Peck CC, Godley PJ. Evaluation of a Bayesian regression-analysis program for predicting phenytoin concentration. Clinical Pharmacy 5: 580–585, 1986
McInnes GT, Brodie MJ. Drug interactions that matter — a critical reappraisal. Drugs 36: 83–110, 1988
McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. British Journal of Clinical Pharmacology 32: 99–104, 1991
Macphee GJA, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgraduate Medical Journal 61: 779–783, 1985
Macphee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 28: 286–294, 1987
Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary tonic-clonic seizures. New England Journal of Medicine 313: 145–151, 1985
May T, Rambeck B. Fluctuations of carbamazepine concentrations during the day for two slow-release preparations. Therapeutic Drug Monitoring 11: 21–24, 1989
Miller R, Rheeders M. Effect of source of population data on phenytoin dosage predictions in black patients. Clinical Pharmacy 8: 56–59, 1989
Mullen PW. Optimal phenytoin therapy: a new technique for individualising dosage. Clinical Pharmacology and Therapeutics 23: 228–232, 1978
Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin, Part I. Clinical Pharmacokinetics 18: 37–60, 1990
Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin, Part II. Clinical Pharmacokinetics 18: 131–150, 1990
Neuvonen PJ, Olkkola KT. Oral activated charcoal in the treatment of intoxications: role of single and repeated doses. Medical Toxicology 3: 33–58, 1988
Pisani F, Perucca E, Di Perri R. Clinically relevant antiepileptic drug interactions. Journal of International Medical Research 18: 1–15, 1990
Privitera MD, Homan RW, Ludden TM, Peck CC, Vasko MR. Clinical utility of a Bayesian dosing program for phenytoin. Therapeutic Drug Monitoring 11: 285–294, 1989
Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Clinical Pharmacokinetics 20: 209–217, 1991
Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clinical Pharmacy 10: 335–358, 1991
Rambeck B, Beonigk HE, Dunlop A, Mullen PW, Wadsworth J, et al. Predicting phenytoin dose — a revised nomogram. Therapeutic Drug Monitoring 1: 325–333, 1979
Rapeport WG, McInnes GT, Thompson GG, Forrest G, Park BK, et al. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. British Journal of Clinical Pharmacology 16: 133–137, 1983
Richens A, Dunlop A. Serum phenytoin levels in management of epilepsy. Lancet 2: 247–248, 1975
Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JWA. The delayed effect of sodium valproate on the photoconvulsive effect in man. Epilepsia 20: 61–68, 1979
Ryan G, Lange IR, Naugler MA. Clinical experience with phenytoin prophylaxis in severe preeclampsia. American Journal of Obstetrics and Gynecology 161: 1297–1304, 1989
Rylance GW, Moreland TA, Butcher GM. Carbamazepine dose frequency requirements in children. Archives of Diseases of Childhood 54: 454–458, 1979
Sander JWAS, Patsalos PN, Oxley R, Hamilton MJ, Yuen AWC. A randomised double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research 6: 221–226, 1990
Smith DB, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA. Age-dependent stereoselective increase in oral clearance of hexobarbitone isomers caused by rifampicin. British Journal of Clinical Pharmacology 32: 735–739, 1991
Swanson PD. Treatment recommendations for anticonvulsant drug therapy in the older patient. Drugs & Aging 2: 92–102, 1992
Tomson T, Almkvist O, Nilsson BY, Svensson JO, Bertilsson L. Carbamazepine 10,11 epoxide in epilepsy: a pilot study. Archives of Neurology 47: 888–892, 1990
Vajda FJE, Drummer OH, Morris PM, McNeil JJ, Bladin PF. Gas Chromatographic measurement of plasma levels of sodium valproate: tentative therapeutic range of a new anticonvulsant in the treatment of refractory epilepsy. Clinical and Experimental Pharmacology and Physiology 5: 67–73, 1978
Vozeh S, Muir K, Sheiner LB, Follath F. Predicting individual phenytoin dosage. Journal of Pharmacokinetics and Biopharmaceutics 9: 131–146, 1981
Vozeh S, Uematsu T, Aarons L, Maitre P, Landolt H, Gratzl O. Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus: a population pharmacokinetic study. Clinical Pharmacokinetics 14: 122–128, 1988
Vree TB, Janssen TJ, Hekster Y A, Termond EFS, van de Dries ACP, et al. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Therapeutic Drug Monitoring 8: 297–304, 1986
Wagner JB. New and simple method to predict dosage of drugs obeying simple Michaelis-Menten elimination kinetics and to distinguish such kinetics from simple first order and from parallel Michaelis-Menten and first order kinetics. Therapeutic Drug Monitoring 7: 377–386, 1985
Weidle PJ, Skiest DJ, Forrest A. Multiple-dose activated charcoal as adjunct therapy after chronic phenytoin intoxication. Clinical Pharmacy 10: 711–714, 1991
Welty TF, Robinson FC, Mayer PR. A comparison of phenytoin dosing methods in private practice seizure patients. Epilepsia 27: 76–80, 1986
Winter ME. Ethosuximide. In Basic clinical pharmacokinetics, pp. 173–177, Applied Therapeutics Inc., Vancouver, 1988b
Winter ME. Phenytoin. In Basic Clinical Pharmacokinetics, pp. 235–264, Applied Therapeutics Inc., Vancouver, 1988b
Winter ME, Tozer TN. Phenytoin In Evans WE et al. (Eds) Applied pharmacokinetics, pp. 493–539, Applied Therapeutics Inc., Vancouver, 1986
Woo E, Chan YM, Yu YL, Huang GY. If a well stabilised patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomised prospective study. Epilepsia 29: 129–139, 1988
Yuen GJ, Taylor JW, Ludden TM, Murphy MJ. Predicting phenytoin dosages using Bayesian feedback: a comparison with other methods. Therapeutic Drug Monitoring 5: 437–441, 1983
Yuen GJ, Latimer PT, Littlefield LC, Mackey RW. Phenytoin dosage predictions in paediatric patients. Clinical Pharmacokinetics 16: 254–260, 1989
Yukawa E, Higuchi S, Ohtsubo K, Aoyama T. Comparison of single point phenytoin dosage prediction techniques. Journal of Clinical Pharmacy and Therapeutics 13: 293–305, 1988
Yukawa E, Higuchi S, Aoyama T. Clinical utility of a new and simple technique for individualising phenytoin dosage. Journal of Pharmacobiodynamics 12: 187–192, 1989a
Yukawa E, Higuchi S, Aoyama T. Clinical evaluation of population pharmacokinetic parameters in phenytoin dosage adjustment. Chemical and Pharmaceutical Bulletin 37: 3363–3366, 1989b
Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid — 1988. Clinical Pharmacokinetics 15: 367–389, 1988
Zaccara G, Messori A, Muscas GC, Albani F, Baruzzi A, et al. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi center evaluation in 282 patients
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomson, A.H., Brodie, M.J. Pharmacokinetic Optimisation of Anticonvulsant Therapy. Clin. Pharmacokinet. 23, 216–230 (1992). https://doi.org/10.2165/00003088-199223030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199223030-00004